Elise Zimmerman

In 2022, I graduated Magna Cum Laude from William & Mary with a B.S. in Biology and a minor in Chemistry. I conducted undergraduate honors research which cumulated in a thesis on the plasticity of the H. pylori methylome in response to acid. Currently, I’m a first-year Ph.D. student in the Systems, Synthetic, and Physical Biology Program at Rice University working in the Chappell Lab on creating a new class of programmable, synthetic RNA-based therapeutics to address global health infectious disease challenges.

Ha Eun Lim

I’m a first year PhD student in Rice University co-advised by Dr. James Chappell and Dr. Laura Segatori. I am working on a project installing RNA sensors in mammalian cells in order to sense inflammation signals and respond with proteins of interest. I graduated from Cornell University with honors in Biomedical Engineering and minor in Computer science in May 2022.

Gene Therapy Development & Manufacturing 2023

Gene Therapy Development & Manufacturing 2023 delivers in-depth discussion on optimised process strategies and technologies for the successful technical development and manufacture of advanced gene therapy products.

Dalton George

My background is in the field of science, technology, and society studies, with a specific focus on the social and ethical dimensions of emerging biotechnologies. I did my PhD at North Carolina State University, where I focused on responsible research and innovation related to environmental and agricultural biotechnologies. My work as a post-doc at Arizona State focuses on the social, ethical, and political dimensions of synthetic biology, with a focus on issues related to biocontainment.

Yangruirui Zhou

Yangruirui Zhou is a third-year Doctor of Philosophy (Ph.D.) student in Computer Engineering Department, Boston University (BU). In Boston University, he is working with Professor Douglas Densmore. Yangruirui got his Bachelor of Engineering (B.E.) in software engineering (Elite Program) from the University of Electronic Science and Technology of China (UESTC)” in 2020. And he was honored with the “Most Outstanding students of UESTC 2019 (成电杰出学生)”, which is the highest honor for undergraduate student in UESTC.

Samuel MD Oliveira

I am a Research Assistant Professor at the Department of Electrical and Computer Engineering (ECE) and the director of the Oliveira Lab (www.oliveiralab.me), a recently created research group at Boston University (BU). In addition, I am the Senior Manager of the DAMP lab (www.damplab.org) at BU.

The Oliveira lab investigates the emergence of microbial community complexity and their underlying interactions in varying environmental contexts and studies microbial community design principles and metrics to help build novel collective behaviors. We hope that breakthroughs in computational and synthetic biology methods will accelerate our knowledge of the links between genetic sequences and intercellular communication to study and engineer the spatiotemporal behavior of biological networks. Among my key collaborators: i) Prof. Chris Voigt (MIT) for improving the predictive DNA design automation tool named Cello (Genetic Circuit Design Automation with Cello 2.0. Nature Protocols).

In my early career, I have published more than 30 articles in journals, conference proceedings, and book chapters, acted as the guest Editor for JoVE, and as a reviewer for Nat. Comm., ACS Synth. Biol., Synth. Biol. J., among others. In addition, I have directly supervised and co-supervised 7 research staff, 7 graduate students (none of whom received their Ph.D. with me), 3 master’s students, and over 14 undergraduates. I was one of the recipients of the Sao Paulo Foundation’s Best Innovative Biotech Product Award in 2019. Based on that, I co-founded a commercial synthetic biology, automation-based company named Doroth (www.doroth.com.br) in Brazil.

Currently, with the support from a $1.4M NSF grant, BU’s Professor Douglas Densmore (co-PI), Prof. Andrews (PI) from UMass Amherst, and my team (technical lead support) are teaming up on an ambitious effort to create microscopic, programmable “living devices” which can detect and neutralize specific toxic contaminants found in drinking water.

Maram Naji

I am a chemical and biological engineering PhD student in the Lucks Lab at Northwestern’s Center for Synthetic Biology. My research centers on targeting riboswitches with antibiotics. I began working toward new infectious disease treatments as an undergraduate researcher in the Nuermberger Lab at the Johns Hopkins Center for Tuberculosis Research. I have also held internships in drug discovery, high throughput biology, and biomarker development at pharmaceutical companies and aim to use synthetic biology to expedite drug discovery and development in my career.

NextGen Omics US 2023

Bringing together leading omics experts from around the world and comprised of three outstanding programmes, delegates can expect to benefit from critical discussions in the future of Next Generation Sequencing, Multi-omic Single Cell & Spatial Analyses and Genome editing in Drug Discovery and Therapeutic Development.

The 2023 event again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data and industry outlook.

Below are some of the confirmed speakers of NextGen Omics US 2023.

Timothy Dahlem, Director of Systems Biology at Recursion Pharmaceuticals

Kamel Khalili, Laura H. Carnell Professor and Chair Lewis Katz School of Medicine at Temple University

Kalina Hristova, Professor of Materials Science and Engineering Institute for NanoBioTechnology at John Hopkins University

Guo-Cheng Yuan, Professor of Computational Biology at Icahn School of Medicine at Mount Sinai

Tirtha Chakraborty, Chief Scientific Officer at Vor Biopharma

Sandra Smieszek, Head of Genetics at Vanda Pharmaceuticals

Maram Naji

I am a chemical and biological engineering PhD student in the Lucks Lab at Northwestern’s Center for Synthetic Biology. My research centers on targeting riboswitches with antibiotics. I began working toward new infectious disease treatments as an undergraduate researcher in the Nuermberger Lab at the Johns Hopkins Center for Tuberculosis Research. I have also held internships in drug discovery, high throughput biology, and biomarker development at pharmaceutical companies and aim to use synthetic biology to expedite drug discovery and development in my career.

Dr. Muhammad Saad Ahmed

The main research interest of Dr. Ahmed is to focus on industrially important metabolites production in microbes through the application of system metabolic engineering and synthetic biology. Previously, Dr. Ahmed developed industrially competitive microbial strains that were capable of producing industrially important secondary metabolites, for instance, β-amyrin, squalene, etc., and these strains are highly efficient for commercialization. Moreover, Dr. Ahmed expanded his research interest toward other industrially important metabolites, i.e., fragrance, flavor, and drugs, that might be in the category of alkaloids, sesquiterpenoids, monoterpenoids, diterpenoids, triterpenoids, and tetraterpenoids. These metabolites are normally used in pharmaceuticals, nutraceuticals, and cosmeceuticals industries as raw materials for the production of medicines, foods, and cosmetics.

Sustainable Chemistry 2023

An innovative 2 day meeting brings together a panel of over 150 prominent leaders and scientists, exploring Sustainable Chemistry, aiming to innovate processes to improve product performance whilst delivering environmental benefits.

Discuss the latest advancements in innovative approaches to sustainable drug development and manufacturing process.

Engage in scientific discussions paving the way towards sustainable chemical synthesis, analytical chemistry and chemical process development.

Dive into the latest technologies driving down pharma sector emissions by implementing “green-by-design” in early drug development phase pipeline projects.

Gain a comprehensive understanding of the peptides and oligonucleotides sustainability landscape; key sessions include application and technology areas.

Join a series of workshops, roundtables, and panel discussions to collaborate with your peers. 2023 sessions include: Greener Peptides, Green Chemical Synthesis, Chemistry in Water, Green Medicinal Chemistry and Green Manufacturing

Biologics 2023

Engage with esteemed pharmaceutical & biotech representatives as well as thought-leaders from academic & research institutions onsite and benefit from attending over 60 presentations. We will be welcoming onsite over 300 delegates for two days of cutting-edge scientific sessions and case studies bringing the latest biologics developments to the forefront of research

Immuno UK: In Person

A two-day event packed with leading speakers, research and cutting-edge presentations on the latest advancements in cancer immunotherapy, with dedicated sessions on different therapeutic modalities as well as case studies on innovative preclinical and translational tools.

Biomarkers 2023

Biomarkers 2023, designed to provide forward-looking insights into the latest trends and tools impacting biomarker research, it brings together leading experts from global pharmaceutical organisations, innovative biotech companies and internationally renowned academic institutions working across multiple therapeutic areas and stages of drug development.

It includes over 90 cutting-edge presentations and discussion sessions, 8+ hours of valuable networking sessions and an exhibition hall showcasing 50+ vendor companies.

Sean Carr

Back to top ⇑